About Enovis Corp
Ticker
info
ENOV
Trading on
info
NYSE
ISIN
info
US1940145022
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
-
Headquarters
info
2711 Centerville Road, Wilmington, DE, United States, 19808
Employees
info
7,367
Website
info
enovis.com
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Metrics
BasicAdvanced
Market cap
info
$1.6B
P/E ratio
info
-
EPS
info
-$24.36
Dividend Yield
info
0.00%
Beta
info
1.65
Forward P/E ratio
info
8.22
EBIDTA
info
$369M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.6B
Average daily volume
info
0.9M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
8.22
PEG ratio
info
1.9
Trailing P/E
info
0
Price to sales
info
0.72
Price to book
info
0.83
Earnings
EPS
info
-$24.36
EPS estimate (current quarter)
info
$0.65
EPS estimate (next quarter)
info
$0.86
EBITDA
info
$369M
Revenues (TTM)
info
$2.23B
Revenues per share (TTM)
info
$39.35
Technicals
Beta
info
1.65
52-week High
info
$49.38
52-week Low
info
$25.47
50-day moving average
info
$30.58
200-day moving average
info
$32.50
Short ratio
info
9.49
Short %
info
20.38%
Management effectiveness
ROE (TTM)
info
-51.02%
ROA (TTM)
info
0.97%
Profit margin
info
-61.22%
Gross profit margin
info
$1.35B
Operating margin
info
1.65%
Growth
Quarterly earnings growth (YoY)
info
153.10%
Quarterly revenue growth (YoY)
info
8.60%
Share stats
Outstanding Shares
info
57.2M
Float
info
56.4M
Insiders %
info
1.57%
Institutions %
info
117.67%
Analyst Insights & forecasts
info

91% Buy

9% Hold

0% Sell

Based on information from 11 analysts.

Average price target

info
$48.11
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.98
$0.92
7.02%
Q4 • 24Beat
$0.81
$0.74
8.90%
Q1 • 25Beat
-$0.64
$0.72
-189.05%
Q2 • 25Missed
$0.75
$0.65
15.38%
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$565M
$-36.7M
-6.51%
Q2 • 25
$549M
$-571M
-104.05%
Q3 • 25
-2.77%
1,454.60%
1,498.88%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$5.02B
$2.44B
48.60%
Q2 • 25
$4.43B
$2.41B
54.35%
Q3 • 25
-11.71%
-1.26%
11.84%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$47.8M
$-49.8M
$6.2M
$3.4M
Q2 • 25
$82.6M
$-56.1M
$-36.9M
$29.1M
Q3 • 25
72.87%
12.57%
-692.31%
755.44%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Enovis Corp share?
Collapse

Enovis Corp shares are currently traded for undefined per share.

How many shares does Enovis Corp have?
Collapse

Enovis Corp currently has 57.2M shares.

Does Enovis Corp pay dividends?
Collapse

No, Enovis Corp doesn't pay dividends.

What is Enovis Corp 52 week high?
Collapse

Enovis Corp 52 week high is $49.38.

What is Enovis Corp 52 week low?
Collapse

Enovis Corp 52 week low is $25.47.

What is the 200-day moving average of Enovis Corp?
Collapse

Enovis Corp 200-day moving average is $32.50.

Who is Enovis Corp CEO?
Collapse

The CEO of Enovis Corp is -.

How many employees Enovis Corp has?
Collapse

Enovis Corp has 7,367 employees.

What is the market cap of Enovis Corp?
Collapse

The market cap of Enovis Corp is $1.6B.

What is the P/E of Enovis Corp?
Collapse

The current P/E of Enovis Corp is null.

What is the EPS of Enovis Corp?
Collapse

The EPS of Enovis Corp is -$24.36.

What is the PEG Ratio of Enovis Corp?
Collapse

The PEG Ratio of Enovis Corp is 1.9.

What do analysts say about Enovis Corp?
Collapse

According to the analysts Enovis Corp is considered a buy.